| Logo | Name | Σ | Employees |
|---|---|---|---|
 |  SYNSIGHT Synsight activity is now integrated into @iktos https://iktos.ai/ https://www.linkedin.com/company/iktos/ Synsight was a company created in 2013, by two co-founders PhD Computer aided drug design: Cyril Bauvais (CEO) and Guillaume Bollot (CSO). In july 2024, Synsight was acquired by @iktos, an AI drug discovery company. Its tech is based on AI drug design and cell imaging, including a proprietary cell based assay named MTBench, to profile compounds modulators of protein-protein and protein-RNA interactions, and protein agregation. criblage virtuel, modélisation moléculaire, dynamique moléculaire, QSAR, drug design, chémoinformatique, and drug discovery 68 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 12 | 1 |
 |  Integrated Biosciences, Inc. Unravelling complex biology with optogenetics, chemistry and computation for small molecule discovery. Our platform is built around a proprietary synthetic biology toolkit, featuring advanced optogenetic tools that enable precise temporal and spatial control of complex pathways and difficult-to-drug targets. Powered by vast proprietary datasets and cutting-edge AI models, our platform accelerates drug discovery and facilitates the generation of novel chemical matter, unlocking solutions for even the most challenging biological systems. biotechnology, aging, drug discovery, machine learning, synthetic biology, optogenetics, artificial intelligence, small molecule, rejuvenation, molecular biology, and novel therapeutics 203 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. Synthetic Biology A.I. - Machine Learning | 1 | 11 |
 | Applied BioMath Model-Informed Drug Discovery and Development (MID3) services, software, and R&D company. Founded in 2013, Applied BioMath uses mathematical modeling and simulation to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk drug research and development. Our Model-Aided Drug Invention (MADI) approach employs proprietary algorithms and software to support groups worldwide in decision-making from early research through clinical trials. The Applied BioMath team leverages their decades of expertise in biology, mathematical modeling and analysis, high-performance computing, and industry experience to help groups better understand their candidate, its best-in-class parameters, competitive advantages, patients, and the best … 10 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: A.I. | 1 | 26 |
 |  Vicore Pharma AB Vicore is an innovative clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Buloxibutid (C21) is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2a development for IPF. AlmeeTM (an investigational medical device in clinical development) is a digital therapeutic based on cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis. Almee has received Breakthrough Device Designation from the FDA, reflecting its potential to have transformative impact. … 23 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 44 |
 | PhoreMost Ltd Drugging the Undruggable® PhoreMost is a new-model drug discovery company based in Cambridge, UK. We are dedicated to ‘Drugging the Undruggable®’ disease targets using our next-generation technology, SITESEEKER®. Using PROTEINi® libraries, this unique drug target identification platform can discern the best new targets for future therapy and crucially, how to drug them, which has the potential to significantly increase the diversity and affordability of novel therapeutics for cancer and other unmet diseases. PhoreMost is building a pipeline of novel drug discovery programmes aimed at addressing a range of diseases, with a mission to accelerate, diversify and rationalise drug discovery. Using … 63 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 6 | 48 |
 | Delta4ai Delta4 is a Vienna-based biotech startup driving the forefront of digital drug discovery and development. Delta4 is driving the forefront of digital drug discovery and development. We leverage a proprietary computational analytics platform "Hyper-C", combining straightforward biomedical testing and clinical validation of candidate drugs. Our unique approach integrates iterative big data/in silico and experimental screens, offering the most efficient matching of clinical indications and compound/drug effects. drug repositioning, drug discovery, compounds, orphan diseases, indication expansion, AI, and omics 67 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Synthetic Biology | 4 | 13 |
 | InterAx Biotech Advanced integration of biological systems, math models and artificial intelligence The company, a spin-out of ETH Zurich and the Paul Scherrer Institute, Switzerland, uses high throughput biochemical screening of compounds integrated into an artificial intelligence and cell pathways mathematical modeling process. This platform unlocks previously intractable targets, shortens timelines for drug discovery from years to months and reduces risks. The company focuses on the generation and optimization of drugs which trigger a specific and well characterized effect on signaling pathways, thus leading to higher therapeutic efficacy and reduced risk of toxicity. The company is specialized in GPCR drug discovery and … 113 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Synthetic Biology | 4 | 15 |
 | AnyGenes® Since more than 10 years, AnyGenes® scientists develop and produce innovative high throughput screening products for signaling pathway analysis. These kits and reagents allow high throughput transcriptomic analysis of a large collection of signaling pathways in many species, biomarkers identification and validation, as well as validation of microarrays results. AnyGenes®, with its innovative & cost effective technologies, products and its proprietary molecular platform, helps scientists to accelerate their projects, publications, and biotech companies for drug development and biomarkers validation. Located in Paris, within Tenon Hospital in the 20th arrondissement, AnyGenes® constitutes a key player in the Biotechnology field. Supported by … 21 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 5 |
 | ANAQUANT Identify and quantify your Host cell proteins thanks to our HCP profiler solution! #TechnologicalCRO #HCP ANAQUANT provides pharmaceutical and biotech companies with high quality services in detection and quantification of proteins by mass spectrometry, in order to speed up their R&D. Thanks to its unique know-how in control and validation of protein quantification, ANAQUANT is a partner of choice for customized assay development of proteins. Our expertise in performing specific and sensitive assays – from one to several dozens of proteins in a small sample volume – significantly contributes to the success of discovery and validation of biomarkers. Our proprietary … 29 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 9 |
 | BioPharmAnalyses Biopharmalysis is an information site that allows you to make an active watch and follow the strategic developments of companies in the biopharmaceutical sector. With biopharmalysis: • You get a synthetic view of recent news from the sector • You are aware of the latest key agreements and mergers and acquisitions • You follow the clinical and regulatory progress of development products • You have access to the latest subsidies, fundraising and IPOs on the stock market Its five databases have more than 13,000 interactive sheets on agreements, clinical trials, fundraising, mergers/acquisitions and the regulatory life of biopharmaceutical products in … 31 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 16 | 2 |
 | Depixus Depixus SAS, based in Paris, is a life science technology company pioneering a groundbreaking technology based on magnetic force spectroscopy. This innovative technology provides real-time analysis of individual biomolecular interactions at scale, enabling researchers to decode disease mechanisms and unlock faster routes to more effective therapies. Single molecule analysis, RNA Drug Discovery, Protein-protein Interaction Analysis, Biophysics, Drug Discovery, Compound Screening, biomolecular interactions, and interactomics 159 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 2 | 57 |
 | Advesya Transforming cancer and autoimmune treatments with unique IL-1RAP targeting approaches Advesya is a pioneering and transformative biotechnology company developing therapies for difficult-to-treat cancers. Haematology & Oncology, Antibody Drug Conjugate, Cell Therapy, and Autoimmune 398 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 11 | 14 |
 | SMARTOX Smartox Biotechnology is specialized in peptide research and manufacturing Smartox Biotechnology is specialized in peptide research and engineering. Peptide synthesis, physiology, pharmacology, neuroscience, ion channel research, toxin, venomous animals, and screening library 336 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology | 0 | 8 |
 | ANTABIO Developing Tomorrow's Antibacterials Antabio is a privately-held clinical-stage biopharmaceutical company developing novel and highly differentiated antibacterial treatments for drug-resistant infections due to CDC and WHO critical priority pathogens. Please visit www.antabio.com and follow us on Twitter @antabio Antibacterial drug discovery, Drug development, and Antibiotic Adjuvant 59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 22 | 22 |
 | DrugOptimal The extension of the pharmacist to support good nursing practices Drugoptimal offers software, extension of the pharmacist, deployable in service to caregivers in order to avoid drug-chemical drug incompatibilities (IPC) by detecting the risks on the prescription and by proposing administration solutions to avoid them. Database of 105,000 couples, validated, and developed from a compilation of 22,000 scientific articles, an IPC prediction model by IA (+4000 physico-chemical parameters per couple) and our own research laboratory in analytical chemistry (dedicated broadband platform to analyze more than 1000 samples per day). Our field of action: - Injectable drugs: support for the choice … 30 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology SaaS | 26 | 9 |
 | Syndivia Syndivia is committed to enhancing treatment options for cancer patients with solid tumors by leveraging the distinctive properties of targeted DAR1 antibody-drug conjugates, which offer improved tumor penetration, stability, and efficacy. Drug development, Biotechnology, Pharmaceuticals, Antibody-drug conjugates, DAR1 ADC, and ADC 156 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 6 | 6 |
 | C4X Discovery Ltd Pioneering drug discovery company exploiting cutting edge technologies to create best-in-class small molecule medicines C4XD is a pioneering Drug Discovery company, combining scientific expertise with cutting-edge technologies to efficiently deliver world‐leading medicines. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced molecular design and patient stratification capabilities, generating small molecule drug candidates across multiple disease indications focused on immuno-inflammation. The Company was founded as a spin-out from the University of Manchester. It has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically and have enabled C4XD … 59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 7 | 37 |
 | Evexta Bio Evexta Bio, formerly #Diaccurate, is a biopharmaceutical company exploring the new frontiers of #oncology in search of daring novel therapeutic approaches with the potential to save lives. Now in the clinic, the French biotech is currently developing two proprietary therapeutic assets with novel mechanisms of action across several indications: - Rupitasertib, formerly DIACC3010, an optimized S6K inhibitor with efficient AKT1/AKT3 control of feed-back loop. The oral anti-tumor agent is expected to enter phase 2/3 clinical trial in refractory ER+ HER2- metastatic breast cancer. - EVX020, formerly DIACC2020, an antibody-drug conjugate program using a sole-in-class KIF20A kinesin inhibitor as payload in … 75 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 6 | 10 |
 | PepKon PepKon is a french biotechnology company founded in 2022. The company develops first-in-class peptides for the treatment of incurable or poor prognosis cancers. These drug-candidates come from over a decade of academic research, resulting in seven scientific publications and two patent families 134 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 11 | 8 |
 | Repositive - no longer trading Accelerating biomedical research by connecting biopharmas with the right preclinical cancer models and CRO partners Repositive is committed to accelerating the development of precision cancer therapies to the clinic by working with biopharmas and Contract Research Organisations (CROs) to improve the predictivity of pre-clinical cancer research. Through its Cancer Models Scout service, Repositive is helping biopharmas to optimise their pre-clinical cancer projects by identifying the most suitable cancer models for their requirements from its world-leading database of over 8000 models, as well as via outreach to an extended network of CRO contacts. Repositive works to connect researchers with the right … 60 similar entities Type: Startup Activities: biotech it services deeptech Technologies: Synthetic Biology | 9 | 1 |
 | Insight Biosolutions Your safety passport for cosmetic ingredients & drug candidates Your partner for toxicological risk assessment requests Using our digital solutions increases the product safety and reduces the product development cost up by 30%. Insight Biosolutions (IBS) with his expert network has developed specialized platforms for in vitro and in silico services. IBS develops digital tools and services for the cosmetics and pharmaceutical industries. Computational Toxicology, in vitro toxicology , Safety assessment, Drug Discovery, Molecular Modeling, Computational Chemistry, CPSR, Pre Clinical screening, ADME, and PBPK 83 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 4 | 4 |
 | Generare Natural molecule discovery, industrialized Natural products have contributed more than 500 molecules to pharmaceuticals. However, conventional methods for discovering new natural products are increasingly ineffective. Generare has developed a revolutionary platform that identifies and expresses a wide range of naturally occurring secondary metabolites, selected by millions of years of bacterial evolution. This platform allows us to reintroduce these lead molecules into clinical pipelines, reopening a validated avenue for therapeutic innovation. genomics, synbio, and microbiology 100 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 8 | 21 |
 | Ecrins Therapeutics Ecrins Therapeutics is a biotechnology company which focuses on the discovery and development of novel anti-cancer compounds from the preclinical phase to phase II clinical proof of concept. In addition to the drug discovery, Ecrins Therapeutics provides a range of products and services for the benefit of our customers in biotechnology companies, universities, public research institutions and in the pharmaceutical industry. The mission of the commercial division of Ecrins Therapeutics is to help medical chemists and drug hunters to discover, characterize and advance their lead compounds through the drug development process. Visit http://ecrins-therapeutics-services.com/ for more information. Our research and production … 47 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology | 3 | 1 |
 | KCAS Bio - Lyon Science Accelerated KCAS Bio - Lyon (Active Biomarkers) operates as a bioanalytical laboratory based in Lyon, France and headquartered in Olathe, Kansas, USA. We offer comprehensive service solutions for the development of both large and small molecules, with extensive capabilities and expertise in pharmacokinetics, immunogenicity, soluble and cellular biomarker analysis for clinical trials. Operating in state-of-the-art BSL2 facilities, our company is GLP certified and ISO 9001:2015 certified, with a unique track-record in the development, validation, and implementation of analytical methods. Our expert team has supported hundreds of studies in multiple therapeutic areas: oncology, infectious diseases, inflammatory pathologies, and neurodegenerative diseases. … 57 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology Data Analytics | 2 | 31 |
 | MEDSENIC New therapeutic targets based on arsenic trioxide (As2O3) Founded in 2010, MEDSENIC is a biopharmaceutical start-up that aims to exploit the new possibilities offered by the therapeutic use of arsenic trioxide (As2O3) and thereby provide a treatment for patients with autoimmune diseases. santé, biotechnologies, bioparma, biopharmaceutical, biotech, health, biotechnology, autoimmune diseases, and maladies auto-immunes 346 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 4 |
 | Ksilink Patient-based drug discovery We design and apply unique patient-based cellular assays for large-scale phenotypic screening, leaning on the power of AI-driven image analysis. Integrated from bed to bench and back to bed, we aim to generate most efficient first-in-class therapeutic molecules for next generation medicine. AI image and data analysis, biology, high content screening, high throughput screening, deep learning, assay development, patient stratification, pyschiatric disorders, and cardiac muscle 235 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: A.I. Synthetic Biology | 4 | 22 |
 | Firalis Molecular Precision CRO & CDMO | Streamlining your Drug Development Process, paving the way for a more Personalized Medicine. Firalis Molecular Precision (FMP) is a fast-growing CRO & CDMO, providing advanced and tailored BioAnalytical Testing services to the Life Sciences sector, based in Huningue, France and in Cambridge, USA. FMP's team leverages its extensive scientific expertise and cutting-edge in-house platforms to provide a range of services, namely sample storage and management, bioanalytical testing, omic data analysis and interpretation, assay development and production - delivering high-quality data to support you along the entire drug development process. FMP's mission is to provide healthcare professionals, … Type: Startup Activities: deeptech biotech Technologies: Data Analytics | 1 | 32 |
 |  BIOptimize BIOptimize is a company that delivers data mining tools and predictive models, using a specific methodology, focused on exhaustivity, simplicity and interactivity. BIOptimize is winner of the NETVA 2013 competition and the French Senate competition "Tremplin d'Entreprises" 2013 as being the best and more innovative and promising french company in the field of biotechnology Specialized in the detection of hidden informations in the scientific data, BIOptimize technology misses not any important information in your scientific data, from in silico Drug Discovery to Clinical Trials Opimization. BIOptimize developped an online sofrware BIOpticloud that can instantly analyze and expalin all your data, … 26 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Data Analytics | 5 | 1 |
 | Fapon Fapon is a global leading life sciences company dedicated to providing integrated solutions and services for diagnostics, biopharma and biotherapy. Integrating a one-stop solution on raw materials, reagents and innovative open instrument platforms, the Company has grown into a leading supplier in in-vitro diagnostics. Fapon boasts advanced innovations in therapeutics technologies and AI algorithm platforms with data insights that contribute to a better and healthier world. Supported by its strong global R&D, manufacturing, sales and service network, Fapon's products have established presence in 68 countries and regions, serving more than 2,500 business partners worldwide. biotechnology, Chemiluminescence Immunoassay, NGS, PCR, biological … 34 similar entities Type: SMB Activities: deeptech Technologies: A.I. Synthetic Biology | 0 | 183 |
 | Sygnature Discovery North America Enabling Success Sygnature Discovery, headquartered in Nottingham (UK), is a world-leading contract research organization for drug discovery. Based in the UK (Nottingham, Alderley Park, Macclesfield, Glasgow) and Canada (Montreal, Laval, Quebec) and with a staff of over 1,000, including over 900 scientists, Sygnature Discovery partners with the global pharmaceutical industry, biotechs and NfP organizations wishing to outsource part of their R&D work. Since 2004, Sygnature Discovery has delivered more than 56 new preclinical compounds, 29 clinical compounds and 1 registered, thanks to the talents of its world-class scientists, who are named on more than 500 patents. The services offered to … 59 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 218 |
 | Liminal BioSciences Liminal BioSciences is a development-stage biopharmaceutical company focused on the discovery and development of novel distinctive small molecule therapeutics that modulate G protein-coupled receptor (GPCR) pathways. The company is developing new proprietary small molecule therapeutic candidates with the intention of developing best-in-class therapeutics for the treatment of unmet metabolic, inflammatory and fibrotic diseases, using its integrated drug discovery platform, expertise in medicinal chemistry and deep understanding of GPCR biology. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. See our social media community guidelines at https://liminalbiosciences.com/social-media-community-guidelines/ 72 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology | 1 | 22 |
 | Drugabilis CRO specialized in pharmaceutical drugability for research Expertise in Human and Animal health solid form characterization and formulation development. We deliver both experimental support and consulting services to biotechnology and pharmaceutical companies, not-for-profit organizations and complementary CROs. We are member of the association AFSSI, 1st French research center in Life Sciences, as a founding member and member of the board of Directors. Since March 2019 Joel Vacus, Drugabilis CEO & CSO, is vice-President of AFSSI. https://www.afssi.fr/ Feel free to contact us in order to exchange about your preclinical drug development! contact@drugabilis.com Lead optimization, Formulation, and Physical form optimization 66 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 7 |
 | GENEPEP - PEPTIDE Peptide Chemistry company for design, synthesis, stability studies and chemical optimisation (SAR studies)- CIR agrement PEPTIDES, PEPTIDE LIBRARIES AND PROTEINS Innovative chemistry for therapeutic, diagnostic and cosmetic applications GENEPEP is a CRO company (with CIR agreement) focused on peptide synthesis & services : - Tools for nanoparticles & surface functionalization - Custom synthesis of peptides, proteins & peptide libraries - Catalog of toxins, peptides & pseudopeptides - Design & synthesis for SAR studies (optimisation of solubility, stability, efficacy,...) - Stability & solubility tests - Partner of European programs, ANR, FUI etc... 375 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 14 |
 | POLYVALAN Proteins Structures Got Easier With Crystallophores Emerged from academic research, POLYVALAN (IBS & ENS Lyon Spin-off company) is a young innovative company founded in December 2016 dedicated to structural biology. POLYVALAN competitive edge is its unique chemical approach allowing significant gain of effectiveness, time and/or precision for protein structure determination that allows an optimal use of the existing large equipments. structural biology, protein crystallization, crystallization screening, nucleating agent, phasing agent, crystallophore, structure determination, X-ray crystallography, and drug design 59 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology | 2 | 3 |
 | NMR - Bio From Molecules to Medicine and Beyond NMR-Bio is a CRO located in Grenoble (France), one of the most vibrant European hubs for structural biology and supplies compounds for the selective labelling of methyl groups in perdeuterated proteins. NMR-Bio also offers a broad range of services for NMR applications: - Custom labelled protein production in bacteria, cell-free system, insect cells, HEK293 and CHO cells - Solution for labelling of your biopharmaceutics especially mAbs and Fabs - High-field NMR data acquisition and analysis (e.g. quality control, spectra assignment, structure calculation, dynamic characterisation). 59 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 2 |
 | ALPHANOSOS OneHealth/AI DeepTech discovering patentable mixes of natural ingredients preserving health and optimizing bioprecesses Alphanosos, a Green One-Health DeepTech company, uses its own Artificial Intelligence algorithms to discover, develop and market active ingredients and products based on blends of extracts from non-pharmaceutical ingredients, in particular edible plants. These active mixtures, some of which are already patented in 15 countries for their antimicrobial activities, are intended for the animal hygiene, dermocosmetics, food preservation and cosmetics sectors, bioprocess optimization and in the longer term, for functional foods and disease treatments. The company began its Research and Development (R&D) activities in mid-2015 and is … 111 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology A.I. | 6 | 4 |
 | CYNBIOSE Exploring together! We support biopharmaceutical research with translational preclinical models. CYNBIOSE is France-based non-clinical research organization. Preclinical CRO, Pharmacokinetics, POC, Efficacy, Immunotherapies, Drug, Early tox, CNS, Infectious diseases, Respiratory diseases, Non clinical, CRO, PK, PD, and TK 69 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 12 | 19 |
 | MonolixSuite Our mission is to accelerate tomorrow’s treatment together MonolixSuite is a powerful, fast, and easy-to-use suite of applications designed for model-informed drug development. With fully interoperable tools for non-compartmental analysis, bioequivalence, population PK/PD modeling, and clinical trial simulations, MonolixSuite accelerates decision-making. It drives smarter, faster, and more effective drug development to improve patient outcomes worldwide Statistics, Pharmacometrics, Modelling and Simulation, Business software, Clinical trials, PKPD, and Non-compartmental analysis 30 similar entities Type: Startup Activities: biotech deeptech it services Technologies: Data Analytics | 1 | 14 |
 | Regulaxis SAS Regenerative Medicine - Growth Disregulation - Oncology REGULAXIS is a French innovative biotechnology company based at BIOCITECH the technology park of life science of Paris North area. The company is engaged in the research, development and licensing of innovative synthetic molecules for use in human therapies. Its mission is to grant licenses of innovative molecules in a pharmaceutical company after the establishment of a phase II clinical record. REGULAXIS leads its R&D on its own premises, particularly in regard to biochemical and biological experiments, and keeps the mastery of the chemical synthesis of its therapeutic molecules. The company develops its … 251 similar entities Type: Startup Activities: biotech healthtech Technologies: Synthetic Biology | 0 | 2 |
 | DiscoveryOrtho Partners A Technology Development and Advisory Company Focused on Medical Devices/Biologics Strategic Advisory Services for both large & small medical device/biologics companies including acquisition, licensing, distribution, joint venture agreements Market, Scientific and Clinical Due Diligence Services Business development Services for venture capital, private equity, hedge funds and investment banking clients & their portfolio companies and clients Product/Device development Strategic Product Postioning including licensing, distribtution and market positioning New Company Formation 520 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology | 0 | 2 |
 | Rostra Therapeutics Restore health and save lives through innovative medicines Rostra strives urgently to bring novel medicines to patients and clinicians with the power to restore health and save lives globally. Through its novel technology platform, Rostra is developing medicines for infectious diseases with an initial focus on invasive fungal infections. Pharmaceutical Discovery & Drug Development and Infectious Disease 59 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology | 0 | 3 |
 | AbLeads AbLeads is a young biotech startup developing innovative solutions in Oncology, through the generation of novel, personalized therapeutic antibodies. Learn More on https://ableads.fr Biotechnology, Oncology, Immunotherapy, Therapeutic Antibodies, and Personalized Medicine 574 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 1 |
 | NEBULA Transforming Drug Target Discovery with Physics-Based dataset-free genAI Partnerships At NEBULA, we revolutionize drug discovery by providing a comprehensive, physics-based dataset-free genAI solution for mapping the full range of therapeutic target conformations. Unlike traditional drug development focused on small molecule screening, our innovative approach delves deep into the dynamic nature of macromolecular targets—proteins, mRNA, antigens—unveiling their multitude of physiological conformations. Our dataset-free technology integrates generative genAI with molecular dynamics, rooted in physical principles, to generate an exhaustive profile of potential target structures without relying on pre-existing data. By enhancing the understanding of drug targets, we empower pharmaceutical and biotech companies … 57 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology A.I. Generative A.I. | 6 | 4 |
 | DATABIOTECHNOLOGY Biovalable Products Advice and amp; d in the field of plant 🍀 - We help you know your products - We optimize the valuation of all your products of natural origin - We are looking for organic uses of your products - We test the activity of your molecules by computer simulation - We bring you pharmacological data Thanks to the establishment of a state of complete art, molecular doce and big data 💾 Molecular doce, consulting, vegetable resources, and simulation 76 similar entities Type: Startup Activities: deeptech Technologies: Data Analytics | 2 | 2 |
 | Veracyte Biopharma Services Gain actionable insights to confidently advance every step of your oncology drug development programs. Veracyte is a global diagnostics company that empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. We provide novel insights, expertise and capabilities that empower our biopharmaceutical partners to confidently advance every step of their oncology drug development programs. precision medicine, Biopharma, biomarker signatures, and Cancer care 41 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Data Analytics | 24 | 74 |
 | Qubit Pharmaceuticals Anything is Druggable - with Quantum Accuracy Qubit Pharmaceuticals brings unparalleled accuracy and precision to drug discovery and design, using quantum physics to develop life-changing treatments for major diseases. We leverage our technologies and expertise to advance 7 fully owned drug discovery programs focusing on cancer resistance and escapement, a growing concern in aging populations, and chronic inflammatory diseases. We also co-develop programs with academia and pharmaceutical partners. Our proprietary ATLAS drug discovery platform unites our technologies based on 30 years of research from renowned scientists and founders, Louis Lagardère (Sorbonne University and CNRS), Matthieu Montes (CNAM), Jean-Philip Piquemal (Sorbonne … 70 similar entities Tags: FrenchTech2030 Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 67 | 71 |
 | Aliri Bioanalysis We deliver data for life > Aliri is committed to solving industry challenges by bringing innovative bioanalysis and spatial solutions to biotech and pharma, as the complexity of the drug development landscape continues to rise. Our mission is to support our customers with bringing life-saving therapies to market with speed and agility. We are focused on providing pharma and biotech companies with bioanalysis lab, spatial bioanalysis, and spatial biology solutions that will bring unique, comprehensive data to enable strategic decision making for lead optimization and strengthen regulatory submissions. MALDI Imaging, ADME analysis, Mass Spectrometry Imaging, Preclinical services, Molecular Imaging, Biodistribution, … 161 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology | 9 | 132 |
 | SYNAXYS Accelerate drug development for neurological diseases SYNAXYS is French biotech specialized in the characterization of the response of the nervous system for nutraceutic, pharmaceutic and veterinary applications. We offer a complete range of R&D services to support drug development, from defining the dose effects in a human model, to identify biological targets and action mechanism, acute and chronic toxicity, or comparison to established treatments. Our field of application: - Drug positioning - Therapeutic evaluation in a diease model - Neuro-oncology - Data generation for IA modeling Neuro-engineering, Neuronal diseases modeling, Neuro-oncology, Autism, Alzheimer disease, and Glioblastoma 101 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 2 |
 | Enzymlogic Enzymlogic is a world leader in the kinetic profiling of compounds to facilitate drug discovery. Enzymlogic is a world leader in the kinetic profiling of compounds to facilitate drug discovery. As experts in the generation and interpretation of kinetic data, we pride ourselves on a proven track record of successful partnerships with worldwide organizations of all sizes, supporting them on a routine basis during the early phases of drug discovery. We use exquisitely tuned assays to deliver accurate, robust and reproducible kinetic data of the highest quality that enhances the identification of compounds with the greatest therapeutic potential. The insight … 25 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 4 | 10 |
 | BioNTech R&D (Austria) GmbH Subsidiary of BioNTech SE, now trading as BioNTech R&D (Austria). Developing novel anti-bacterials. BioNTech R&D Austria GmbH (formerly: PhagoMed Biopharma GmbH) is a fully owned subsidiary of BioNTech. The team in Vienna focuses on developing novel anti-bacterial drugs for persistent bacterial infections. Biotech 56 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology | 2 | 7 |
 | CellSine Discover your favorite frequencies to boost your drug discovery business CellSine provides devices and software that make advanced electrochemical impedance spectroscopy easily accessible to any microbiological researcher. It delivers a platform tool for a that enables a wide variety of biochemical studies. Biotechnology, Cell culture monitoring, Proteïn - Proteïn interactions, Suspension cultures, Receptor signaling, Biofilm maturation, and T lymphocyte activation 206 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 4 |
 | Platinum Discovery Multiomics research for precision medicines Platinum Discovery offers a cutting-edge Tumour-to-Target Platform, specialising in cancer vaccine development through the identification of tumour-specific neoantigens. We provide a comprehensive, end-to-end drug discovery pipeline, supporting clinical trial research and translational science for patient samples. Our multidisciplinary team brings together expertise in biology, clinical sciences, multi-omics technologies, bioinformatics, and computational sciences, enabling a deep understanding of the biological processes critical to drug development. We excel at integrating diverse scientific domains to deliver holistic, innovative solutions. With extensive experience in designing and managing complex research programmes, we assemble tailored teams of experts, drawing on our … 112 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 4 |
 | Pharmacelera Mine enhanced chemical space. Design superior candidates Quantum-Mechanics and Machine Learning Drug Discovery. Pharmacelera develops proprietary Computer-Aided Drug Design software and provides access to its technology through flexible licensing options and computational chemistry services. The methodology mines an unexploited chemical space, finding starting points with larger chemical diversity and improving the creativity of chemists. The technology is based on accurate Quantum-Mechanics algorithms, Machine Learning and High-Performance Computing (HPC) and it derives from more than 25 years of research. Pharmacelera helps companies in Target Identification, Hit-Identification, Hit-to-Lead and Lead Optimization drug discovery stages by finding novel hits, improving ligand binding properties … 22 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. - Machine Learning A.I. | 1 | 24 |
 | McSAF Chemical tools for bioconjugaison & biodrugs McSAF is a Deeptech company specialized in Bio-Organic & Bio-Conjugates Chemistry, developing innovative technologies for improved targeted therapies. Its core expertise covers Therapeutic Peptides and Proteins, Antibodies, and Drug Conjugates. The team has a strong background in synthetic selective chemistry, and a real expertise in bioconjugation, including specific designs of Antibody Drug Conjugates (ADCs) with own proprietary coupling technology. Plus, the company has now a pipeline of three products in oncology incorporating McSAF Inside technology with the ambition to bring new biodrugs on the market solving unmet medical needs. Bioconjugation, Biopharmaceuticals, Antibody Drug Conjugates, … 77 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 6 |
 | OPPILOTECH LTD Navigating Biology, Discovering Drugs Oppilotech have developed a high-resolution platform based on systems biology and machine learning to model biological processes in cells. We use the models to simulate biological processes in order to identify viable drug targets and discover new biology. The company is building a pipeline of first-in-class drug discovery programmes based on the identified targets. 86 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology A.I. A.I. - Machine Learning | 1 | 11 |
 | MolDrug Chemoinformatics and modeling solutions to optimize your drug candidates. MolDrug (a ProtoQSAR company) is a group specializing in the design and optimization of molecules through Machine Learning-powered chemoinformatics and structural bioinformatics. Our models allow for the prediction of molecular properties (QSAR) and detailed interaction analyses (molecular modelling). We work with all types of compounds, including small molecules, peptides, nanomaterials, mixtures... Our tools allow for the prediction and assessment of physicochemical, biological, pharmacological, and/or (eco)toxicological properties of substances with an array of advantages: - faster results - saving money and resources - reduce animal testing (3 Rs) - regulatory validity (REACH, … 61 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 4 |
 | ResoTher Pharma Building on innovative science to create treatments for patients in need ResoTher Pharma ApS is a biotechnology company focused on developing novel and effective peptide therapeutics for cardiovascular disease by targeting inflammation. Biotechnology, Drug Development, and Pharmaceutical Industry 662 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 17 |
 | Greenpharma S.A.S. From Nature to market Who we are : Greenpharma is a CRO SME of 12 people, specialised in natural compound studies for cosmetic, food and pharmaceutical industries. Built around an innovative technological platform, Greenpharma succeeded to gather expertise in wide and complementary fields such as chemoinformatic, pharmacognosy, medicinal & analytical chemistry, pilot scale extraction and formulation. This has led to a unique know-how in natural compound & extract selection, extract purification, metabolite measurement, homology modelling, virtual screening (e.g. SelnergyTM), lead optimisation, ADMET prediction and database building. Greenpharma approach has led to several patents on bioactive (natural or synthetic) molecules and … 9 similar entities Type: SMB Activities: biotech deeptech Technologies: Bio sourced materials | 4 | 16 |
 | InFocus Therapeutics Innovating a New Class of Medicines to Drug the Undruggable InFocus is a discovery-stage biotechnology company dedicated to true innovation for novel therapeutic modalities. We are integrating unique experimental technologies with a state-of-the-art algorithm-driven drug discovery platform, to develop next-generation small molecule drugs against undruggable targets at unprecedented scale. 119 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 2 | 11 |
 | ACROBiosystems Where Proteins and Innovation Advance Biomedicine ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation. The company spans across the globe and maintains offices, R&D centers, and production bases in 12 different cities within the United States, Switzerland, England, Germany, and China. ACROBiosystems Group has established numerous long-term and stable partnerships with the world’s top pharmaceutical enterprises, including Pfizer, Novartis, and Johnson & Johnson, and numerous well-known academic institutes. The company comprises of several subsidiaries such as … 64 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology | 4 | 146 |
 | OncoDNA OncoDNA is a genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic diseases. The company helps clinicians, academic researchers and biopharma companies to outsmart molecular complexity with the mission of delivering the promise of precision medicine. The company not only provides clinical guidance for the treatment and real-time monitoring of late-stage cancer patients but also supports research and drug development in cancer and genetic diseases. Since its early days in 2012, OncoDNA has grown into a corporate group of companies with world-renowned expertise. The Group offers a unique portfolio that combines NGS services, biomarker … 69 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 12 | 48 |
 | Cellarity Rewriting the rules of drug creation Cellarity is fundamentally redesigning the way drugs are created. By shifting the focus from a single target to the underlying cellular dysfunction, the company unravels the complexity of disease biology to create medicines that are out of reach with the target-based drug discovery approach. Founded by Flagship Pioneering in 2017, Cellarity has developed a platform that utilizes proprietary AI models trained on over 30 million single cell transcriptomes to uncover novel actionable biology and create non-intuitive drug candidates in a vast array of diseases. The company currently has programs ongoing in several disease areas … 281 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Synthetic Biology | 4 | 104 |
 | Confo Therapeutics Exploiting the conformational complexity of GPCRs to innovate drug discovery Confo Therapeutics’ unparalleled technology stabilizes functional conformations of GPCRs (G protein-coupled receptors) to uncover a wide range of previously inaccessible GPCRs as drug targets. This technology platform combined with the pharmacologic and biologic insight it provides, allows Confo to build a multi-indication pipeline of drug candidates with the potential to transform therapeutic outcomes for patients with severe illnesses lacking disease-modifying treatments. Confo Therapeutics was spun out of Vrije Universiteit Brussel (VUB) and VIB in 2015. Supported by international life-science focused investors and led by an experienced team of entrepreneurial professionals … 66 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 72 |
 | Anuva Creating the world’s most diverse Genomic Bio/Data Bank to help uncover novel biological pathways for drug discovery Anuva is creating the world’s most diverse Genomic Bio/Data Bank to help uncover novel biological pathways for drug discovery. Anuva is a translational research company that is creating the most diverse Genomic Bio/Data Bank of Asian Populations, which is being utilized for research & development within the pharma industry. Our cohorts and biorepository allow for follow-on clinical and translational studies, which greatly empower drug development opportunities. IndiaCHIP, Genomics, Genomics - Emerging markets, Genomics - R&D, Genomics Data Platform, Genomics - India, bioinformatics, and … 65 similar entities Type: Startup Activities: biotech deeptech Technologies: Data Analytics Synthetic Biology | 8 | 61 |
 | Alesta Therapeutics Oral small molecules for rare diseases Alesta Therapeutics is a pioneering company based in Leiden, Netherlands, dedicated to the development of first-in-class small molecules that target GCN2. Our commitment to advanced, high-quality chemistry has led us to develop a clinical candidate with an extensive pre-GLP toxicology and CMC package. 137 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 10 |
 | MedFacts Drug discovery with cutting-edge AI technology We’re pioneering the use of AI and shaping the future in drug discovery, significantly cutting costs and development times. Our unique AI algorithms have generated novel drug candidates and identified enhancements for existing therapies more efficiently than traditional methods, setting us apart in the competitive landscape. Artificial Intelligence, Data Science, Health, Medicines, and Drug development 146 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 1 |
 | PharmEnable Therapeutics Harnessing the power of chemical novelty, diversity and 3-dimensionality to develop innovative small molecule drugs PharmEnable is a biopharmaceutical company utilizing AI to discover effective small-molecule medicines for disease targets that are inaccessible to antibodies. With our proprietary AI-enabled drug discovery platform, chemSEEK, we explore new chemical spaces and discover novel small molecules with antibody-like specificity and selectivity. We are developing a pipeline of wholly owned therapeutics with initial focus on oncology and neurology. We also engage in drug discovery partnerships across a range of disease areas where accessing the target poses a significant challenge. PharmEnable is based in Cambridge, … 111 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 6 | 20 |
 | Guilford Street Laboratories At Guilford Street Laboratories (GSL), a UCL spin-out, we are dedicated to helping our clients achieve their research objectives. Leveraging machine learning-driven mass spectrometry, we deliver highly precise and sensitive biomarker panels, specializing in the analysis of protein, lipid, and metabolite markers. Whether your focus is on early disease diagnosis, drug discovery, collaboration as a partner in an EU Horizon consortium, clinical trials, or personalized medicine, our team is here to help. Mass Spectrometry, Biomarker, CRO, and Rare Disease 25 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. - Machine Learning Data Analytics | 0 | 11 |
 | Inoviv Accelerating the Development of New Medicines with Targeted Proteomics Inoviv uses a novel technology platform based on targeted proteomics to support pharmaceutical companies with biomarker test development. Proteomics, Biomarker Discovery, Translational Biomarkers, Mass Spectrometry, Targeted Proteomics, Discovery Proteomics, Biomarkers, Precision Medicine, Proteomic Analysis, Proteome Profiling , Quantitative Proteomics, Liquid Chromatography Mass-Spectrometry (LC-MS), Post-Translational Modifications (PTMs), Quantitative Biomarkers, Clinical Proteomics, Immuno-Precipitation Mass Spectrometry (IP-MS), Proteins, LC-MS Proteomics, Proteomics Services, and Protein Identification 165 similar entities Type: Startup Activities: deeptech healthtech biotech Technologies: Synthetic Biology | 0 | 35 |
 | Destiny Pharma Limited - In Administration Mark Smith and Stephen Cork were appointed Administrators on 21 August 2024, and act without personal liability. Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections … 76 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 15 |
 | Oncostellae Novel small-molecule drugs in immunology, fibrosis and women health Clinical-stage biotech company founded by serial entrepreneurs and owned by private & institutional investors. Discovery and development of new chemical entities with strong IP and worldwide rights targeting indications with high unmet medical need in immunology, fibrosis and women health. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, Inflammation and autoimmune diseases, IP generation, IBD, Ulcerative Colitis, Crohn's disease, Fibrosis, and Uterine fibroids 249 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 10 |
 | Arcede Pharma Aiming to provide improved treatments for chronic respiratory diseases through new, innovative drug substances Aiming to provide improved treatments for chronic respiratory diseases through new, innovative and patent protected substances, thereby reducing suffering and ameliorating quality of life for patients. 380 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 1 |
 | Galactica Biotech Galactica Biotech provides a drug repurposing method to identify novel applications for molecules in the market and in development for major and orphan diseases, reducing risk for patients and time and cost for companies. Our Mission With our specialized knowledge we are targeting to set new standards in the pharmaceutical industry adding value to old drugs and contributing to the health of people. Drug Discovery, Molecule characterization, Drug repurposing, and Novel compound applications 290 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Synthetic Biology | 0 | 1 |
 | CytoReason The First Cell-Centered Computational Model of Human Disease CytoReason is a tech company transforming biopharma’s decision-making from trial and error to data-driven using an AI Platform of computational disease models. With its extensive database of public and proprietary data, the company maps human diseases – tissue by tissue and cell by cell. Researchers of all levels rely on CytoReason’s technology to make data-driven decisions across the drug development life cycle. Scientists can identify potential targets, prioritize indications, and stratify patient populations. Program leaders can compare drugs across multiple diseases or multiple drugs within a single disease. C-level executives can gain … 79 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Synthetic Biology | 9 | 132 |
 | FluoSphera The only company with a suite of systemic and high-throughput in vitro drug discovery solutions FluoSphera S.A. is the only company providing a suite of high-throughput, systemic, in vitro drug discovery solutions. Its proprietary chip-free platform uses flexible 3D cell systems that mimic the complex biology of the human body to rapidly and precisely study human response to systemic drug delivery. FluoSphera offers four distinct drug discovery solutions: (1) multiplexing for target selectivity, (2) measuring systemic efficacy and toxicity, (3) systemic biomarker identification, and (4) translational species optimization. 60 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 8 | 5 |
 | MEDIBIOFARMA SL To make disease-modifying treatments available to patients with serious or life-threatening conditions Medibiofarma S.L is a clinical-stage biotechnology company founded in 2016 by a group of professionals with extensive experience in Drug Discovery in the pharmaceutical industry. We aim to generate innovative and high quality research programs based on the modulation of clinically validated therapeutic targets for the treatment of cancer and non-cancer diseases. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, IP generation, IBD (Colitis, Crohn), Oncology, CNS, and Synaptopathies 540 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 9 |
 | Galmed Pharmaceuticals Ltd. A clinical-stage drug development biopharmaceutical company for liver, metabolic & inflammatory diseases Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Our lead compound, AramcholTM, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study. We are also collaborating with the Hebrew University in the development of Amilo-5MER, a 5 amino acid synthetic peptide. Our corporate headquarters is located in Tel Aviv, Israel. For more information about Galmed, please visit our website at: www.galmedpharma.com 21 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 11 |
 | ASTRA Therapeutics Precision Drugs against Eucaryotic Pathogens ASTRA Therapeutics is a Drug Discovery company with a mission to design and develop novel, precision engineered drugs against a whole range of Eukaryotic Pathogens. 505 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 4 |
 | Acceleron Pharma Accelerating drug discovery to transform patients' lives Effective 11/22/21, Acceleron Pharma Inc. is now a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada) http://merck.com Biopharmaceuticals, Orphan Disease Therapeutics, Rare Diseases, and Serious Diseases 605 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology | 6 | 67 |
 | AUM Biosciences Advancing precision oncology therapeutics designed to deploy multi-faceted inhibition to reverse cancer resistance AUM Biosciences is focused on advancing a clinical pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance biotech, oncology, drug development, Asian-biotech, Precision medicine, Digitalhealth, cancer, and small molecules 550 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 17 |
 | Array BioPharma Inc. Array BioPharma Inc. (NASDAQ: ARRY) is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Eight registration studies are currently advancing related to seven Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics). We have locations in Boulder, CO; Cambridge, MA; and Morrisville, NC. Small molecule drug discovery and development., oncology, biotechnology, melanoma, and colorectal cancer 80 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 110 |
 | AXIOS Senolytics Innovation at the service of your health and well-being. Pharmaceutical company, R & AMP; D dedicated to the development and marketing of senolytic compounds, food supplements and aging medications, age -related degenerative diseases and cancer. 322 similar entities Type: SMB Activities: deeptech biotech healthtech Technologies: Synthetic Biology | 1 | N/A |
 | Debiopharm we develop for patients Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, we conduct clinical development and then select large pharmaceutical commercialization partners for out-licensing to maximize patient access across the globe. Through this specialized business model, Debiopharm can focus on the development of prescription drugs that target unmet medical needs in oncology and bacterial infections. Debiopharm completed the development and has licensed out 2 compounds: - Triptorelin, the active substance of Decapeptyl®/Trelstar®/Pamorelin®/Triptodur® 1, 3 and 6-month formulation and Moapar®/Salcacyl® -Oxaliplatin, the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat® If your university … 79 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 15 | 488 |
 | Selvita Integrated Drug Discovery | Drug Development | Contract Research Selvita is one of the largest preclinical contract research organizations in Europe, driven by a clear mission: to offer a comprehensive scope of services bridging the gap between early drug discovery and the clinical stage of drug development. biotechnology, pharmaceuticals, drug discovery, preclinical research, bioanalytical development services, bioinformatics, systems biology, proteins, genomics, proteomics, autoimmune disorders, regulatory studies, medicinal chemistry, agrochemical, industrial chemistry, and assay development&screening 504 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 4 | 771 |
 | Cellomatics Biosciences Ltd Our expertise, Your discovery Cellomatics Biosciences Ltd. (www.cellomaticsbio.com) is a laboratory-based Contract Research Organisation (CRO) specialised in Oncology/Immuno-Oncology, Immunology/Inflammation and Respiratory therapeutic areas. Based at Colwick Quays Business Park, Nottingham UK, our experienced scientific team offers bespoke and innovative preclinical in vitro bioassay services to support our client’s drug development programmes. We work with diverse group of global clients including early start-ups, virtual/small to medium sized Biotechnology and Pharmaceutical companies. Multiplex Immunoassay, Target and biomarker validation, In vitro functional assays, Molecular Biology, Receptor binding, Toxicity testing, Immuno-Oncology, Oncology, Immunology, Inflammation, and Respiratory 376 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 19 |
 | KCAS Bio A contract research organization (CRO) advancing the latest in drug development with leading sponsors, worldwide. KCAS Bio is a top-tier contract research organization (CRO) that has 45 years of experience with both large pharma and biotech sponsors, providing comprehensive bioanalytical drug development services from early discovery through registration. We have supported more than 300+ FDA approved drugs on the market, developed 5,000+ proprietary and non-proprietary assays to date, and undergone 18 FDA audits with no major findings. Our presence in multiple locations throughout the US and Europe - and with a strategic alliance in Australia - allows us to serve … 145 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 7 | 356 |
 | Causeway Sensors Limited Causeway Sensors uses nanotechnology to provide better candidate selection during drug development. The company spun-out after years of high-impact research at Queen's University Belfast. Our unique nanochip platform brings real-time, label-free kinetic analysis to areas of biotherapeutic production where such data cannot currently be collected. More data at critical points of production helps pharma companies ensure that only the best drug candidates progress to clinical trials. The platform can be incorporated into a multitude of form factors, ranging from a high-throughput screening instrument to an in-line cell culture monitoring tool. Biosensing, Protein - Protein Interactions, Binding Kinetics, Biotechnology, Biotherapeutics, Antibody … 91 similar entities Type: Startup Activities: biotech deeptech Technologies: Data Analytics Synthetic Biology | 3 | 11 |
 | NuMedii NuMedii discovers and de-risks effective new drugs by translating Life Sciences Big Data into therapies with a higher probability of therapeutic success. The Company’s proprietary and dynamic Big Data technology, developed in Atul Butte’s lab at Stanford University and licensed exclusively to NuMedii, consists of hundreds of millions of human, biological, pharmacological and clinical data points that the company has normalized and annotated. The company integrates these data with proprietary network-based algorithms to find both drug candidates and biomarkers predictive of efficacy for diseases. 64 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. Data Analytics | 2 | 5 |
 | OMass Therapeutics OMass Therapeutics is a private pharmaceutical company, focused on structural mass spectrometry to discover novel medicines. The company uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulating complex formation. These methods are being applied to drug discovery for a variety of complex targets, including membrane receptors, addressing severe unmet medical needs. OMass is backed by Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures and British Patient Capital. 60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 14 | 85 |
 | Sygnature Discovery Sygnature Discovery is a world-leading integrated drug discovery contract research organization based in the UK and Canada with headquarters in Nottingham (UK). Additional sites are located in Alderley Park, Macclesfield, and Glasgow (UK), as well as Montreal and Quebec City (Canada). Its team of over 1,000 employees, which includes 900 scientists, partners with global biotech, pharma and NFP organizations. Since 2011, Sygnature Discovery has delivered 50 novel pre-clinical and 30 clinical compounds, with its scientists named on over 170 patents. Therapeutic areas of expertise include oncology, inflammation and immunology, neuroscience, metabolic diseases, infectious diseases, fibrotic diseases, and more. Founded in … 79 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 15 | 664 |
 | ADOCIA "Innovative medicine for everyone, everywhere" "Innovative medicine for everyone, everywhere" Listed on the Euronext stock market, Adocia is a clinical-stage biotech company specialized in the development of best-in-class medicine relying on innovative formulations of already-approved therapeutic proteins. Adocia is specialized in diabetes and obesity. The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients. For more information, visit our website: www.adocia.com For careers offers, please click to the following link : https://www.adocia.com/careers/adocia-careers/ Therapeutic proteins, BioChaperone®, Next-generation injectables for diabetes treatment, Ultra-rapid Insulin, Multi-agents injectable combination, Diabetes, Metabolic … 59 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 8 | 90 |
 | Frontage Laboratories, Inc Advancing drug discovery and development through integrated laboratory, analytical, and clinical services Frontage Laboratories, Inc. is a CRO that provides integrated, science-driven, product development services throughout the drug discovery and development process to enable pharmaceutical and biotechnology companies to achieve their development goals. Comprehensive services include drug metabolism and pharmacokinetics, analytical testing and formulation development, preclinical and clinical trial material manufacturing, bioanalysis, preclinical safety and toxicology assessment and early phase clinical studies. Frontage has enabled many biotechnology companies and leading pharmaceutical companies of varying sizes to advance a myriad of molecules through development and file regulatory submissions in the United … 107 similar entities Type: SMB Activities: biotech deeptech manufacturing Technologies: Synthetic Biology | 1 | 671 |
 | BioPharmGuy Worldwide Biotech Company Database BioPharmGuy is a website that functions as a directory of companies in the biotechnology, pharmaceutical, medical device & life science industries. We offer services for businesses as well as job seekers. The site is constantly being updated to ensure we have the most accurate and high quality, free-to-use database. 55 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology | 0 | 2 |
 | VRG Therapeutics Regional leader in preclinical R&D with a world-class protein evolution tech platform for CGT applications Our mission is to cure diseases via targets and MoAs that cannot be reached with traditional approaches. Leveraging our unique platform, we optimize peptides/proteins of natural origin using directed evolution to create cutting-edge CGT products or peptide-based pharmaceuticals. VRGT’s management and staff members were selected based on their international research experience and outstanding pharma industry achievements. Our people have outstanding professional expertise in preclinical/clinical R&D and scientific project management, pharmacology, business development and medical marketing. For years, they have worked in the most prestigious academic … 158 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 26 |
 | Quanterix Discovery Fueled by Ultra-Sensitivity Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognosis and precise treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research … 92 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology | 16 | 446 |
 | Ranomics Ranomics offers innovative solutions for protein engineering, drug discovery, genomics research and synthetic biology Ranomics offers high throughput solutions for protein engineering, drug discovery, genomics research and synthetic biology. Using our VariantFind and VERG genomics platforms, Ranomics offers partners the a scalable solution to engineer and screen genetic variants in a wide range of model organisms. Our industry leading DNA Variant libraries and high-throughput cell assays help researchers to hit their research objectives faster and with better results than traditional methods. Over the years, we have worked with top biotech and pharma companies in the US and worldwide. Our partners … 186 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 5 |
 | Biosortia, Inc. Unlocking the Hidden Chemistry of Microbiomes for Next-Generation Therapeutics with ISMM • Expanding Customer Pipelines Biosortia Pharmaceuticals is pioneering a revolutionary approach in drug discovery through its Industrial Scale Microbiome Mining (ISMM) technology. By accessing the vast, untapped chemical diversity found within natural microbiomes, We unlock a hidden world of small molecules that play crucial roles in cellular signaling and disease processes. These small molecules, often referred to as the "drug-like dark matter" of cellular biology, have been largely inaccessible until now. Our technology allows for the large-scale harvesting and exploration of these compounds, providing an unprecedented opportunity to discover … 69 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. Data Analytics Synthetic Biology Generative A.I. A.I. - Machine Learning | 1 | 10 |
 | Pharvaris Pioneering science for patient choice Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically … 71 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 117 |
 | Calico Biosystems Predicting life-changing drugs for patients with cancer Calico Biosystems is on a mission to help pharma companies create effective, affordable drugs faster to counter cancer multi-omics assay, computational modeling, drug efficacy prediction, combination therapy, and Cell and virus-based therapeutics' efficacy 543 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 2 | 1 |
 | Medivir AB Improving life for cancer patients through transformative drugs Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a smart, targeted chemotherapy designed to selectively treat liver cancer cells and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Medivir's share … 64 similar entities Type: SMB Activities: biotech deeptech manufacturing Technologies: Synthetic Biology | 1 | 46 |